Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | MAPKAPK2 | P49137 | 9/20 | 0.44 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2935810 | 0.85 | PRMT1 (0.49) | MAP4K4MAPKAPK2CYP17A1NAMPTAURKA | |
| SCHEMBL3757588 | 0.77 | MAP4K4 (0.47) | MAP4K4MAPKAPK2CYP17A1NAMPTKDR | |
| SCHEMBL3759290 | 0.76 | NAMPT (0.43) | MAPKAPK2CYP17A1NAMPTAURKAAURKB | |
| SCHEMBL13305748 | 0.75 | MAP4K4 (0.53) | MAP4K4MAPKAPK2CYP17A1AURKAAURKB | |
| SCHEMBL21578861 | 0.74 | CYP17A1 (0.50) | MAP4K4MAPKAPK2CYP17A1NAMPTAURKA | |
| SCHEMBL1818637 | 0.73 | AURKA (0.53) | MAP4K4MAPKAPK2CYP17A1NAMPTAURKA | |
| SCHEMBL13055402 | 0.72 | CYP17A1 (0.59) | MAP4K4MAPKAPK2CYP17A1NAMPTPSMB8 | |
| SCHEMBL1455451 | 0.72 | KDM4E (0.65) | MAP4K4CYP17A1NAMPTAURKAAURKB | |
| SCHEMBL12750936 | 0.72 | CYP17A1 (0.50) | MAP4K4CYP17A1NAMPTPSMB8 | |
| SCHEMBL20132392 | 0.71 | HPGD (0.56) | CYP17A1NAMPTAURKAAURKBPSMB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9540372-B2 | Pyrido[2,3-b]pyrazin-8-substituted compounds and their use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2017-01-10 | — | — | US | disclosed |
| US-9540372-B2 | Pyrido[2,3-b]pyrazin-8-substituted compounds and their use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2017-01-10 | — | — | US | disclosed |
| US-20160002230-A1 | PYRIDO[2,3-B]PYRAZIN-8-SUBSTITUTED COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-01-07 | — | — | US | disclosed |
| US-20160002230-A1 | PYRIDO[2,3-B]PYRAZIN-8-SUBSTITUTED COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-01-07 | — | — | US | disclosed |
| US-9155737-B2 | Pyrido[2,3-B]pyrazin-8-substituted compounds and their use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-10-13 | — | — | US | disclosed |
| US-9155737-B2 | Pyrido[2,3-B]pyrazin-8-substituted compounds and their use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-10-13 | — | — | US | disclosed |
| US-20150182526-A1 | PYRIDO[2,3-B]PYRAZIN-8-SUBSTITUTED COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-07-02 | — | — | US | disclosed |
| US-20150182526-A1 | PYRIDO[2,3-B]PYRAZIN-8-SUBSTITUTED COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-07-02 | — | — | US | disclosed |
| US-8912191-B2 | Pyrido[2,3-B]pyrazin-8-substituted compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-12-16 | — | — | US | disclosed |
| US-8912191-B2 | Pyrido[2,3-B]pyrazin-8-substituted compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-12-16 | — | — | US | disclosed |
| US-20120238568-A1 | Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2012-09-20 | — | — | US | disclosed |
| US-8198279-B2 | Pyrido[2,3-b]pyrazin-8-substituted compounds and their use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2012-06-12 | — | — | US | disclosed |
| US-8198279-B2 | Pyrido[2,3-b]pyrazin-8-substituted compounds and their use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2012-06-12 | — | — | US | disclosed |
| US-8198279-B2 | Pyrido[2,3-b]pyrazin-8-substituted compounds and their use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2012-06-12 | — | — | US | disclosed |
| US-20100298320-A1 | Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| US-20100298320-A1 | Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| US-20100298320-A1 | Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| EP-2229391-A1 | PYRIDO[2,3-B]PYRAZINE-8-SUBSTITUTED COMPOUNDS AND THEIR USE | Cancer Research Technology Limited (GB) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009077766-A1 | PYRIDO[2,3-B]PYRAZINE-8-SUBSTITUTED COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-06-25 | — | — | WO | disclosed |
| WO-2009077766-A1 | PYRIDO[2,3-B]PYRAZINE-8-SUBSTITUTED COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238568-A1 | Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use | BRAF, NRAS, RAF1 | MAP4K4 135/4885MAPKAPK2 87/4885CYP17A1 2857/4885 |
| US-20150182526-A1 | PYRIDO[2,3-B]PYRAZIN-8-SUBSTITUTED COMPOUNDS AND THEIR USE | BRAF, NRAS, RAF1 | MAP4K4 135/4885MAPKAPK2 87/4885CYP17A1 2857/4885 |
| US-20160002230-A1 | PYRIDO[2,3-B]PYRAZIN-8-SUBSTITUTED COMPOUNDS AND THEIR USE | BRAF, NRAS, RAF1 | MAP4K4 135/4885MAPKAPK2 87/4885CYP17A1 2857/4885 |
| US-20100298320-A1 | Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use | BRAF, NRAS, RAF1 | MAP4K4 135/4885MAPKAPK2 87/4885CYP17A1 2857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.